ABSTRACT-
dependent relaxation in pre-constricted rat aorta, pulmonary artery and trachea. The onset and duration pattern of these relaxing effects were similar to those caused by nifedipine, an L-type Ca 21 channel blocker. Calciseptine relaxed the contraction of rat aorta provoked by an L-type channel agonist, Bay K 8644. This relaxation was not affected by 1V~-nitro-L-arginine, indomethacin or propranolol. Calciseptine and FS2 inhibited the contraction caused by acetylcholine in guinea pig ileal longitudinal muscle. In case of in vivo study using anesthetized rats, calciseptine, FS2 and nifedipine showed depressor effects. The hypotensive effects of the two peptides were more potent and sustained than that of nifedipine. These findings show that both synthetic calciseptine and FS2 have similar biological activities like nifedipine, an L-type Ca 21 channel blocker. In addition, these two peptides with large molecular weights may be unique and useful tools for studying the Ca 21 channel.
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Voltage-dependent Ca 21 channels play important roles in the transmitting of signals by neurons and in the contraction of cardiac or smooth muscle cells. There are four types (L-, N-, T-and P-types) of voltage-dependent Ca 21 channels (1) . The L-type channel is widely distributed in excitable cells and has the largest conductance. L-Type channel blockers that are organic molecules, such as 1,4-dihydropyridines and phenylalkylamines, have been developed and used for the treatment of cardiovascular disorders and other diseases (2) .
The selective blockers are very important as pharmacological tools for studying the physiological role of the subtypes of Ca2+ channels. The N-type Ca 21 channel in neural cells is blocked by a natural peptide toxin, wconotoxin GVIA (3) . A peptide toxin from the funnelweb spider, w-agatoxin IVA, has been recently reported to block the P-type Ca 21 channel present in cerebellar Purkinje cells (4) .
Although there are many L-type blockers as mentioned above, no natural substance had been known until the recent discovery of calciseptine in black mamba venom (5) . This peptide consists of 60 amino acid residues with eight cysteine residues (Fig. 1) . The binding site of calciseptine should be the extracellular surface for the Ca 21 channel because of its large molecular weight. This is useful for studying the Ca 21 channel because the binding site for the Ca 2+ blockers that are small organic molecules is still controversial. The receptor site for the 1,4-dihydropyridines is proposed to be in the extracellular surface domain of the a,-subunit of the channel (6) . In contrast, Regulla et al. (7) reported that the 1,4-dihydropyridines bind to the putative cytosolic domain of the Ca2+ channel.
We searched for peptides homologous to calciseptine in the data base PRF/SEQDB of the Protein Research Foundation. The search identified snake venom peptide FS2 as a homologous peptide (8) (Fig. 1) ; This peptide is a three amino acid substituted homolog with much less toxicity than other snake venoms (9) . Although FS2 is the third most abundant component isolated from black mamba venom, the pharmacological properties of FS2 had not been studied precisely so far.
We have synthesized calciseptine and FS2 by the solution procedure. In this study, we examined its biological activities in vitro and in vivo. The activities of synthetic calciseptine and FS2 were determined in rat aorta, pulmonary artery and trachea and also in guinea pig ileum. We also studied the effect of these peptides on blood pressure in anesthetized rats. The activities of the two peptides were compared with those of a control drug, nifedipine, as a common L-type Ca" blocker.
A part of the preliminary account of this work about calciseptine has been given in abstracts (10). . Each peptide consists of 60 amino acid residues with eight cysteine residues, respectively. The differences of the amino acid residues are at positions 5, 30 and 32. The intramolecular disulfide bonds of calciseptine and FS2 were the same compared to other short snake toxins (18) and the details of disulfide bond will be described elsewhere.
Synthesis of peptides
Calciseptine and FS2 were synthesized as reported previously (11) . Briefly, all peptides were synthesized by means of the solution procedure applying the maximum protection strategy (12) and recently deprotected solvent systems that are useful for the synthesis of slightly soluble peptides (13) . The fully protected peptides were unblocked by anhydrous hydrogen fluoride and oxidized for disulfide bond formation in ammonium acetate buffer in the presence of reduced and oxidized glutathione (GSH/GSSG). The crude products with disulfide bonds were purified by ion-exchange high performance liquid chromatography (HPLC), followed by preparative reversed-phase HPLC. The homogeneity of the final product was confirmed by amino acid analysis, thin layer chromatography, reversed-phase HPLC, ion-exchange HPLC and capillary zone electrophoresis. The purity of each preparation was over 99% of the final purified peptide.
Relaxing activities on vasculatures and trachea
The relaxing activities on precontracted smooth muscles were determined in rat thoracic aorta, pulmonary artery and trachea preparations. Smooth muscle contractions were determined as reported previously (14) . Thoracic aortas, pulmonary arteries and tracheas were removed from decapitated male Sprague-Dawley rats (260 -290 g) and placed in Krebs-Henseleit solution of the following composition: 118 mM NaCI, 4.7 mM KCI, 2.5 mM CaC12 • 2H2O , 0.6 mM MgSO4.7H2O, 1.2 mM KH2PO4, 25 mM NaHCO3 and 11 mM glucose. The smooth muscles were cleaned of adipose and connective tissue and cut into ring preparations (about 3 mm). The pulmonary arterial rings were isolated from the right branch. The trachea ring (two to three cartilages) was isolated from the portion just above the bronchus. These ring segments were mounted on stainless steel wires and suspended from force displacement transducers in tissue baths with a water-jacket (371C) and containing 10 ml Krebs-Henseleit medium, gassed with (95% 02-5% C02). The tissues were equilibrated for 1 hr under an optimal resting load of 0.5 g (aortas) or 0.3 g (pulmonary arteries and tracheas), maximally contracted with 80 mM KCI, and then washed and allowed to dilate to baseline tension. The changes of muscle tension were measured with an isometric recording systern (Star-Medical SUL2GR, PA-011; San-Ei 8K21; Tokyo). Before the determination of muscle relaxation, smooth muscles were precontracted with 40 mM KC1 as reported previously (5) . In these experiments, 100070 relaxation represents the resting tension before the muscle contraction.
Inhibiting activities on ileum contraction
The inhibiting activities on acetylcholine (ACh) contraction were determined in guinea pig Real longitudinal muscle preparations (15) . Briefly, ilea were removed from decapitated male guinea pigs (600 -800 g). Segments
(approximately 20 mm) were cut at the portion about 100 mm proximal to the ileo-caecal junction and placed in Krebs-Henseleit solution. These segments were cleaned of extraneous connective tissue and mesenteric arteries. The ileal longitudinal muscle preparations were suspended on isotonic transducers in tissue baths (10 ml) containing Krebs-Henseleit medium. The preparations were equilibrated for 1 hr under an optimal resting load of 0.5 g, maximally constricted with 1 ,uM ACh, then washed and allowed to dilate to resting tension. Muscle tension was measured with an isotonic recording system (StarMedical IA-001, San-Ei 8K21). Contracting responses by ACh (1 pM) were determined 10 min after calciceptine and FS2 treatment. Inhibiting activities were expressed as a percentage of the responses compared to ACh (1 pM) contraction before the peptide treatments. Fig. 2 . Vasorelaxing effects of calciseptine (CaS) and FS2 on precontracted rat thoracic aorta induced by 40 mM KC1.
Hypotensive activities
Male Sprague-Dawley rats (260 -290 g) were anesthetized with pentobarbital (50 mg/kg, i.p.), and a tracheotomy was performed. Arterial blood pressure was determined directly through a femoral arterial cannula. Heart rate was continuously monitored by counting the pulse rate of this aortic pressure. Blood pressure and heart rate were monitored with an electronic system (Century Technology CP-01, Inglewood, CA, USA; Star Medical PA-011, Star Medical HR-001; San-Ei 8K21). Peptides were injected as a bolus (0.5 ml/kg) through a femoral venous cannula. 
Relaxing activities in vasculatures
The biological activities of synthesized calciseptine and FS2 were measured in precontracted rat thoracic aorta (Fig. 2) , by the same method as used for natural calciseptine (5). The onset and duration pattern of the relaxing effect of synthetic calciseptine were the same as those of the natural product as reported previously (5). The onset was within two minutes, and it took 40 -50 min to reach the plateau. The common L-type Cat' blocker nifedipine showed a similar pattern of activity (data not shown). The cumulative dose-response curves of calciseptine, FS2 and nifedipine were obtained (Fig. 3) . At 10 nM-1 1M, calciseptine and FS2 showed dose-related relaxation on precontracted rat aortas. The average ED50 values in this experiment were 74.9:L-13.9 nM (n = 9) and 93.6:L 8.0 nM (n=6) for calciseptine and FS2, respectively. Nifedipine had a stronger potency than these peptides, with an ED50 value of 47.7.± 8.8 nM (n = 7) in this preparation.
Calciseptine and FS2 demonstrated vasorelaxing activity in the pulmonary artery. The cumulative doseresponse curves are shown in Fig. 4 . Calciseptine caused dose-dependent relaxation with an ED50 value of 62.5 ± 9.2 nM (n=6). FS2 showed a stronger tendency than calciseptine, with an ED50 value of 44.5±2.9 nM (n=6). The ED50 value of nifedipine was 79.4 ± 19.1 nM (n = 7).
Synthetic calciseptine (0.1 1M) produced relaxation in rat aorta and pulmonary artery precontracted with 0.1 teM norepinephrine (data not shown). The patterns of relaxation were the same as those observed in the same vasculature precontracted by 40 mM KCl as shown in Fig. 2 . The onset was within two min, and it took 40-50 min to reach the plateau (approximately 90% relaxation). These results indicate that the Ca 21 channel is activated by adrenergic receptor as reported previously (16), and calciseptine blocks this activated Ca 21 channel. Relaxing activity in Bay K 8644 contracted aorta We observed the relaxing effect of synthetic calciseptine on precontracted rat aorta by Bay K 8644, a specific Ltype Ca 2+ channel agonist (Fig. 5) . The rat aorta was pretreated with 8 mM KC1 to induce contractility. Other vasodilatation was prevented by pretreating (approximately 20 min before) the preparation with three blockers: propranolol (10 rM) to block the f3-adrenergic receptor, indomethacin (5 rM) to block the synthesis of prostaglandins and 1VG-nitro-L-arginine (100 p M) to block the nitric oxide (NO) synthase. The upper panel of Fig. 5 shows the control response of Bay K 8644 contraction in rat aorta. Contraction was sustained until the preparation was washed. Calciseptine (0.1 1M) completely blocked the contraction produced by Bay K 8644 (lower panel of Fig. 5 ). These findings indicate that calciseptine specifically blocks the L-type Ca" channel. FS2 showed the same result in rat aorta (data not shown).
Relaxing activities in trachea
In the trachea ring precontracted with 40 mM KCI, calciseptine at 0.1 pM also showed relaxing activity. The pattern of relaxation was similar to that observed with the vasculature preparation. The cumulative dose-response curves of calciseptine, FS2 and nifedipine are shown in Fig. 6 . Calciseptine, FS2 and nifedipine relaxed precontracted tracheas dose-dependently. The order of relative potency in the trachea was FS2 > calciseptine > nifedipine. The ED50 values were 6.94-±:1.08 nM (n=6), 9.75 ± 2.93 nM (n = 7) and 24.3 ± 3.3 nM (n = 6) for FS2, calciseptine and nifedipine, respectively.
Inhibiting activities on ACh contraction in ileum
Calciseptine inhibited the contraction with ACh (0.1 ,uM) in guinea pig ileal longitudinal muscle. The doseresponse curves of calciseptine, FSZ and nifedipine for the inhibiting effects on ACh contraction are shown in Fig. 7 .
The ED50 values were 32.6 ± 7.5 nM (n = 5), 51.7::L 13.7 nM (n=6) and 15.4± 1.8 nM (n=6) for nifedipine, FS2 and calciseptine, respectively. Hypotensive activities Calciseptine, FS2 and nifedipine showed depressor activity in anesthetized rats. The mean blood pressure level of anesthetized rats before peptide administration was 90-100 mmHg. The dose-response curves of acute hypotensive effects are shown in Fig. 8 . The responses represented changes in blood pressure within 5 min after administration of the peptides and nifedipine. The hypotensive potencies of calciseptine and FS2 were greater than that of nifedipine. At a higher dose, FS2 showed stronger activity than calciseptine.
The time course study of the hypotensive effect is shown in Fig. 9 . The mean blood pressure level of the anesthetized rats before peptide administration was 90-100 mmHg. The doses used in this study were equipotent with those in Fig. 8 . The durations of the hypotensive activities of calciseptine and FS2 were longer than that of nifedipine. In addition, these peptides showed biphasic depressor effects; acute within 5 min, followed by a long sustained phase. Nifedipine showed only the acute hypotensive phase. The duration times were 20, 80 and 120 min or more for nifedipine, FS2 and calciseptine, respectively. The second phase of depressor activity was stronger with calciseptine than FS2. The hypotensive activity was not inhibited by propranolol (1 pmol/kg, i.v.), indomethacin (5 mg/kg, i.v.) or IV'-nitro-L-arginine (10 pmol/kg, i.v.) (data not shown).
Calciseptine caused only a small increase in heart rate (approximately 10-40 beats/min), although it had a strong hypotensive effect. This finding agrees with the comment of De Weille et al. (5) that calciseptine leads to very significant decreases of arterial pressure with only small effects on cardiac rhythm. This increase in heart rate was not dose-dependent (data not shown). FS2 caused a small heart rate change, and the effect was not dose-dependent.
Nifedipine showed a similar effect on heart rate, like calciseptine. Fig. 3 . Fig. 8 . Dose-response curves of acute hypotensive effects of calciseptine (0, n=7), FS2 (0, n=6) and nifedipine (0, n=6) in anesthetized rats. Mean blood pressure levels of anesthetized rats before peptide administration were 90-100 mmHg. Significant differences are the same as in Fig. 3 .
We have demonstrated that our synthetic calciseptine showed the same relaxing activity on precontracted rat aorta as the natural calciseptine. The synthetic calciseptine relaxed Bay K 8644 contracted rat aorta. Its relaxing activities were similar to those of nifedipine in various in vitro and in vivo preparations. Our synthetic calciseptine binds to a 1,4-dihydropyridine recognition site of the Ltype Ca" channel in rat synaptosomal membranes (17) . These data demonstrated that synthetic calciseptine is a specific inhibitor of L-type Ca" channels.
The biological activities of synthetic FS2 were very similar to those of the calciseptine both in vitro and in vivo. In addition, FS2 bound to a 1,4-dihydropyridine recognition site of the L-type Ca 21 channel in rat synaptosomal membranes (0. Yasuda et al., personal communication), like calciceptine. These findings indicate that FS2 is a specific inhibitor of the L-type Ca 21 channel.
Calciseptine and FS2 caused a sustained decrease in blood pressure, with the effect being biphasic: short-lasting, followed by a long-lasting phase. In contrast, nifedipine showed only a short-lasting decrease, and the decreased response recovered to the blood pressure level before the administration of nifedipine within 20 min. These biphasic decreases in blood pressure by the two peptides were not abolished by pre-administered propranolol, indomethacin or N -nitro-L-arginine.
The major mechanism for the hypotensive effects of these peptides may be caused by the peripheral vasorelaxing activities of these Ca 21 channel inhibitions, because changes in heart rate were small. The first phase may be caused by the main site of the Ca 21 channel inhibition, because the patterns of the depressor effects of the two peptides are similar to that of nifedipine. The second phase of calciseptine or FS2 may be caused by its interaction with a binding site different from the Ca2+ channel and/or different sensitivity of the vasculature to the relaxing activity. The precise site of actions of these two phases of hypotensive effects remains to be investigated.
The pharmacological profiles of FS2 in different assay preparations were similar to those of calciseptine. These results may be due to the sequence homology of the two peptides. However, there are differences in the charged group of the side chain of these two peptides at positions 30-32 (Fig. 1 ). FS2 has a more positive charge than calciseptine around this area. Calciseptine has the acidic side chain of glutamic acid with a negative charge at position 32. In contrast, FS2 has the basic side chain of histidine with a positive charge at position 30. These differences of the charged group may influence the potency of the two peptides. The potencies of FS2 differed from those of calciseptine both in vitro and in vivo. In pulmonary artery, trachea and ileum, FS2 showed stronger potency than that of calciseptine. In hypotensive activities, FS2 showed stronger activity than calciseptine at a high dose. These results indicate that the conformation of these two peptides might be different and/or the effect of charged groups on the binding sites of L-type Ca 21 channels might be slightly different, and these differences may influence the potencies of the peptides in the different tissues. The differences in the mechanisms of action of these two peptides will be clarified by using patch clamp or other methods.
In conclusion, the studies in this report show the synthetic calciseptine and FS2 to be specific inhibitors of the L-type Ca 21 channel. These two peptides, both large molecules, would be useful tools for studying the binding site of the L-type Ca2+ channel. Furthermore, in the future, we must perform a structure-activity relationship study on calciseptine by substituting amino acid residues around positions 30 and 32. 
